I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

AAO 2023

-
Coming soon
03:00 PM
Duration 5mins San Francisco, USA
Personalized Faricimab▼ Dosing Increased the Proportion of Patients With nAMD Achieving Q16W Dosing in TENAYA/LUCERNE
Chaudhary V, Ambresin A, Kotecha A, Souverain A, Swaminathan B, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 5mins San Francisco, USA
Faricimab▼ Treat-and-Extend–based Dosing Dynamics in the Phase 3 YOSEMITE/RHINE Trials
Lim J, Yonekawa Y, Figueroa M, Pearce I, Gibson K, Jain N, Shildkrot E, Souverain A, Yang M, Willis J, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 5mins San Francisco, USA
Faricimab▼ Rapidly Dries the Retina in Patients With nAMD
Klein K, Gale R, London N, Kotecha A, Margaron P, Swaminathan B

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 5mins San Francisco, USA
Clinical Outcomes of Patients With DME Presenting With ≤ 20/50 Visual Acuity Treated With Faricimab▼ and Aflibercept
Talcott K, Holekamp N, Zarbin M, Ding A, Tabano D, Lu X, Ahmed A, Yang M, Stoilov I, Amador M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 5mins San Francisco, USA
Automated Segmentation of Hyperreflective Foci in DME: Greater Volume Reduction With Faricimab▼ in Phase 3 YOSEMITE/RHINE
Singh R, Chakravarthy U, Maunz A, Von Schulthess E, Patel K, Bachmeier I, Jones I, Cohen Y, Gibson K, Glittenberg C, Fauser S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 5mins San Francisco, USA
Faricimab▼ Reduces Macular Leakage vs Aflibercept in Patients With DME
Kolomeyer A, Eichenbaum D, Sivaprasad S, Nudleman E, Csaky K, Wang T, Haskova Z, Shildkrot E, Amador M, Mar F, Goldberg R, Camino A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 1min San Francisco, USA
Elevatum Study Design and Rationale: A Phase 4 Trial of Faricimab▼ (VABYSMO) in Underrepresented Patients With DME
Cunningham M, Coney J, Scott A, Amador M, Chang J, Stoilov I, Meldorf M, Gonzalez L

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:22 PM
Duration 6mins WEST 3004
How Effective is Anti-ANG2 and Anti-VEGF (Faricimab▼) for Neovascular AMD With Pigment Epithelial Detachments?
Jennifer I. Lim - M.D., FARVO

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:40 PM
Duration 6mins WEST 3005
Real-world Outcomes and Treatment Patterns With Faricimab▼ in AMD
Sophie J. Bakri - MD.

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:41 PM
Duration 6mins WEST 3006
Long Term Clinical Outcomes of anti-VEGF Therapy for Retinal Vein Occlusion: An Overview of Current Data
Michael Ip, MD

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:12 PM
Duration 6mins WEST 3006
Clinical Outcomes of Patients With DME Presenting With ≤ 20/50 Visual Acuity Treated With Faricimab▼ and Aflibercept in the YOSEMITE/RHINE Clinical Trials: A Pooled Subcohort Analysis
Marco A. Zarbin - MD, PhD, FACS

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:12 PM
Duration 6mins WEST 3006
Regional Variance in the Enrollment of Underrepresented Patients in US Clinical Trials of Diabetic Macular Edema
M. Ali Khan, MD, FACS

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar